A headshot photo of Paul Lockman.

Paul Lockman, PhD, BSN

Asst. Vice President of Experimental Therapeutics Professor

Contact Information

Email
Phone
304-293-0944
Address
PO Box 9530
2037D HSC
Morgantown, WV 26506

Affiliations

  • Pharmaceutical Sciences
  • Department of Neuroscience
  • Mary Babb Randolph Cancer Center
  • Rockefeller Neuroscience Institute

Graduate Training

  • PhD, Pharmaceutics, Texas Tech University Health Sciences Center

Fellowship

  • Phillip Morris Foundation and Texas Tech School of Pharmacy
  • Experimental Therapeutics and Pharmacokinetics

Research Interests

Dr. Lockman earned his B.S. in Nursing from West Texas A&M University, after which he practiced in intensive care, clinical toxicology and emergency medicine, before earning his Ph.D. (Pharmaceutical Sciences) at Texas Tech University Health Sciences Center. Dr. Lockman was an Associate Professor and Associate Dean for Outcomes Assessment and Accreditation at Texas Tech University before transitioning to West Virginia University. Currently, Dr. Lockman is the Douglas Glover Endowed Chair of Basic Pharmaceutical Sciences at West Virginia University School of Pharmacy. He also serves as the Associate Director for Translational Research at the Mary Babb Randolph Cancer Center.

Dr. Lockman’s primary research focus is on understanding why chemotherapy has limited distribution, and ultimately fails in brain metastases of breast cancer.

Research Topics

  • Drug distribution across the Blood-brain barrier
  • Brain tumors
  • Parkinson's disease
  • Stroke

Grants and Research

Research Interests
Chemotherapy distribution into brain tumors and metastases
Nanoparticle drug delivery to brain
Effects of nicotine and or smoking on drug distribution
 
Recent and Current Funding
biOasis; Drug Company Contract  “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer; Survival Project”
National Cancer Institute, National Institutes of Health, Bethesda, MD. 1R01CA166067-01A1 “Prevention and Treatment of Brain Micro-metastases of Breast Cancer”
NEKTAR Therapeutics; Drug company contract “Pharmacokinetics and efficacy of NEKTAR-102 in brain metastases of breast cancer”
biOasis; drug company contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer”
Department of Defense, Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter.
Department of Defense, Breast Cancer Research Program. # BC050006. Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer.
Microtransponder; Medical Device Grant “Feasibility of microstimulation for targeted BBB disruption.” 
Minority Health Research and Education Grant program. State of Texas Board of Higher Education; Minority Health Research and Education Grant. Innovations in Competency Education: Strengthening the Pipeline.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. Development of Novel Treatments for Nicotine Addiction.”

Recent Publications

[2018]

  • Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti MV, Nolan RL, Lockman PR.  Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. Accepted 27 Mar 2018. 
  • Mohammad AS, Griffith JI, Adkins CE, Shah N, Sechrest E, Dolan EL, Terrell-Hall TB, Hendriks BS, Lee H, Lockman PR (2018). Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharm Res. 2018 Jan 9;35 (2):31.
[2017]

[2016]

[2015]

[2014]

View More Publications

Lab Personnel

Rajaganapathi Jagannathan, PhD

Research Assistant

Afroz Mohammad, MS

PhD Candidate

Tori Terrell-Hall, BS

PhD Candidate

Neal Shah, PharmD

PhD Candidate